вторник, 15 марта 2016 г.

Market Extra: Why share volume of tiny biotech Celator is surpassing that of Apple

Market Extra: Why share volume of tiny biotech Celator is surpassing that of Apple


Investors on Tuesday are more interested in what may be the newest way in more than 40 years to better treat a type of deadly blood cancer than they are the next iteration of Apple Inc.'s iPhone. shot into the stratosphere late Monday after the company reported a late-stage, Phase 3 study showed its drug Vyxeos significantly improved the average survival of patients with acute myeloid leukemia , compared with the current standard-of-care chemotherapy.



from Biotech News